How much is Sera Medicines worth in 2026?

Sera Medicines has a current valuation of N/A based on their Early Stage VC round and secondary market data.

How much funding has Sera Medicines raised?

Sera Medicines has raised N/A in total funding across 1 funding rounds.

Sera Medicines

Biotechnology

Sera Medicines valuation and funding history | Last updated: January 1, 2023 | 1 funding rounds

Current Valuation

N/A

As of January 1, 2023

Total Funding Raised

N/A

Across 1 round

Last Round

Early Stage VC

Amount undisclosed

Last Funding

Jan 2023

Funding date

Capital Efficiency

N/A

Valuation / Funding

Funding History & Valuation Timeline

Complete history of all funding rounds and valuation milestones

Date	Round	Amount	Post-Valuation	Growth
January 1, 2023	Early Stage VC	Undisclosed	N/A	-

Valuation Analysis

Current Valuation Metrics

Sera Medicines is currently valued at N/A as of January 1, 2023.

Track Sera Medicines Valuation Updates

Get notified when Sera Medicines raises new funding or valuation changes

Explore More Data

Detailed analysis for Sera Medicines

Secondary Market Price

Real-time pricing data and trends

Valuation Tracker

Historical valuation changes

Funding History

Complete funding round timeline

Secondary Price History

Historical transaction data

All Investors

Complete list of all investors

View 5 companies free

Create a free account to unlock Sera Medicines's valuation history, funding rounds, and growth metrics.

No credit card required

What is Sera Medicines Worth in 2026?

Sera Medicines is a leading private company in the Biotechnology sector. Track Sera Medicines's valuation history, funding timeline, and implied market value from secondary transactions on Premier Alternatives.

How Sera Medicines Valuation is Determined

Private company valuations like Sera Medicines's are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including revenue growth, market opportunity, competitive positioning, and investor sentiment.